Reagents, Reference Materials & Laboratory Chemicals Synthetic Peptides and Laboratory Reagent Manufacturer Expands Premises for New Product Development


Severn Biotech Ltd, manufacturer of Synthetic Peptides and Laboratory Reagent products, has announced the recent acquisition of Unit 1 Park Lane Kidderminster. The additional building, covering over 4000ft2, refl ects the company’s expansion plans going forward and its need to increase the laboratory space necessary to develop new products and services.


With the existing premises, the additional building gives a combined total of over 8000ft2, divided into manufacturing production laboratories, quality control, packaging, storage, distribution and sales.


Unit 1 will initially be used for packaging and storage, with the development of further laboratories and a clean room facility at a later stage. The investment made by its founding Managing Director Andrew Smart, MSc. M.IoD. is part of a £250K funding development package of private capital necessary to take the fi rm to the next level within the company’s business plan.


Severn Biotech manufactures research products, synthetic peptides, conjugates and biological/ immunological molecules used in antibody formation. The development of new sterile products, cell biology buffers and laboratory consumables for life science researchers represents continued investment in new products and processes.


28785pr@reply-direct.com


New Line of Kits and Reagents for Gene-Editing Launched


Horizon Discovery™ have announced it has launched the fi rst products and services from its new GENASSIST™ range of gene editing kits and reagents that enable easier, robust implementation of CRISPR and rAAV gene editing experiments.


The current GENASSIST offering comprises both off-the-shelf reagents for using CRISPR editing technology and a unique kit combination of these reagents to allow customers to generate their own CRISPR-ready cell lines that constitutively express Cas9-nickase. Using such cell lines provides a quick start for customers, enabling them to make further modifi cations to the cell line more effi ciently than if they were starting fresh each time. Horizon is also launching a new service for the design, manufacture and most importantly validation of CRISPR RNA guides, in order to maximise the likelihood that gene editing will occur as expected.


Dr Darrin M Disley, CEO, Horizon Discovery, commented: “The launch of our fi rst CRISPR kits mark the next stage in Horizon establishing itself as the leader in the gene editing fi eld. Recent advances in gene editing technology, with techniques such as rAAV, ZFN and CRISPR, have had a revolutionary effect on translational genomics. Horizon’s goal is to make these developments accessible to the wider scientifi c audience, through contract manufacturing, do-it-yourself products and high-end technical support services. As the only company who can offer all of these techniques singularly or in combination we can ensure that researchers, on their own or with our advice, can make an informed choice of which technology or combination of technologies to deploy to gain the correct answer to the biological question being asked.”


“CRISPR and Cas9 technology is making gene editing broadly accessible to researchers,” said Eric Rhodes, Horizon’s VP R&D and CTO. “Our new GENASSIST kits, combined with access to rAAV, ZFN, and CRISPR technologies, give researchers an invaluable suite of tools to determine the function of endogenous gene alterations and their effect on disease and therapeutic responses. We’re also utilising all three technologies within Horizon to expand on our collection of over 550 X-MAN™ genetically defi ned cell lines and endogenous pathway reporter cell-based assay kits.”


Horizon plans to launch additional products and services in the near future as part of GENASSIST to further enable researchers working in the gene editing fi eld. 29387pr@reply-direct.com


Raman and Fluorescent Certifi ed Reference Material


A new Certifi ed Reference Material from Starna Scientifi c provides an elegant way of estimating the ultimate sensitivity of high-performance spectrofl uorometers.


Conventional solution measurements with concentrations near the detection limit are impractical because sample preparation is diffi cult and there is a real risk of contamination. This novel Reference uses the Raman scattering exhibited by ultra-pure water to simulate the fl uorescence of a very low fl uorophore concentration. The Reference Material comes with a Certifi cate of Validation and full instructions for use.


Starna Scientifi c is accredited to ISO Guide 34 and ISO 17025 and all Starna references carry a lifetime guarantee.


29414pr@reply-direct.com


Flow Cytometry Reagents Range Expanded


On 1 April Alpco began offering a new specialised panel of fl ow cytometry reagents from Cytognos SL, a supporting participant of the EuroFlow™ Consortium. The Plasma Cell Screening Tube (PCST) can be used to help discriminate between aberrant and clonal plasma cells. Also included in this suite of products are ASR designated EuroFlow™ reagents and three additional screening tubes specifi cally designed to accomplish standardisation of immunophenotyping in leukemia and lymphoma sample populations.


In addition to these reagents, Alpco also offers the Infi nicyt™ software program for simple and fast analysis of fl ow cytometry data fi les.


“Our growing partnership with Cytognos will benefi t all of our customers in the fl ow cytometry space,” explained ALPCO President, Sean Conley. “The products in the EuroFlow™ panel and Infi nicyt™ software suite provide a more effi cient workfl ow combined with the most powerful data analysis software released to date. This combination will prove an invaluable asset to any fl ow cytometry lab.”


Cytognos General Manager, Jorge Bensadon, said: “We are very pleased to announce the release of the PCST in the North American market through our partner Alpco. This EuroFlow™ tube proved suffi cient for the specifi c identifi cation, enumeration and discrimination between normal/reactive and aberrant plasma cells, being used for the initial screening of Plasma Cell Dyscrasias.”


29529pr@reply-direct.com Merck Millipore and VWR Extend Western European Distribution Agreement


Merck Millipore have announced a new non-exclusive, preferred distribution agreement for Western Europe with VWR. The contract includes a range of Merck Millipore products and reagents for chemical and microbiological analysis, which are mainly used in quality control solutions for the pharmaceutical, food and beverage and chemical industries, as well as products for research in the fi eld of organic synthesis and biosciences.


“The new contract continues an important relationship with one of Merck Millipore’s largest distributors and reinforces our commitment to providing our existing customers easy access to high quality products,” noted Robert Yates, Head of Merck Millipore. “We will give VWR access to more Merck Millipore products and expect with VWR’s wide geographic coverage across Western Europe we will be able to reach a larger customer base.” The contract replaces an exclusive chemical distribution agreement between Merck Millipore and VWR covering Western Europe originally signed in 2004. Under the new preferred agreement, Merck Millipore is free to engage with other organisations, but VWR will remain the distributor of choice through December 2018.


“VWR is proud to renew its agreement with Merck Millipore, to provide customers with high quality chemical and analysis products,” said Peter Schuele, President European Lab Business, VWR. “We enable science with our assurance of supply through an excellent logistic infrastructure and our ability to combine the chemical offering with consumables, equipment, instrumentation and our rapidly growing service business. Merck Millipore is a very important part in our chemical portfolio and the high value we can bring to our customer base”.


29616pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84